Cue Biopharma (CUE) Proxy filing summary

Executive summary

• Interim President and CEO appointed following the resignation of the previous CEO and board member, effective March 26, 2026.

• Board size reduced to six directors as a result of the resignation, with no replacement nominee named.

• A separation and release of claims agreement was executed with the outgoing CEO.

Voting matters and shareholder proposals

• One director nominee withdrawn due to resignation; remaining nominees continue to stand for election.

• Proxy cards and voting instructions for the withdrawn nominee will not be counted for that individual but remain valid for other matters.

• No changes to other proposals or items to be acted upon at the annual meeting.

Board of directors and corporate governance

• Board composition changed with the resignation of a director and reduction in board size.

• Interim leadership established with the appointment of the Chief Financial and Business Officer as Interim President and CEO.